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Background
Control of blood vessel tone is central to vascular home-
ostasis. Here, we show that metabolism of tryptophan to
kynurenine by indoleamine 2,3-dioxygenase (IDO)
expressed in endothelial cells contributes to arterial vessel
relaxation and the control of blood pressure.
Methods
We used three models of inflammation: infection of mice
with malarial parasites (Plasmodium berghei), LPS-induced
endotoxemia, and transient cerebral ischemia (stroke
model). Blood pressure was determined via tail-cuff, and
vascular function studies carried out in wire bath systems.
IDO expression and activity were assessed by IHC and
HPLC, respectively.
Results
All models of inflammation caused expression of IDO in
micro-vascular endothelial cells, resulting in decreased
plasma tryptophan and increased kynurenine. In malaria
infection and endotoxemia, IDO expression was associ-
ated with hypotension. Pharmacological inhibition of
IDO increased blood pressure in systemically inflamed
mice, but not in mice deficient for IDO or interferon-γ,
which is required for IDO induction. In endotoxemic
mice, IDO deficiency partially attenuated the observed
hypotension. In experimental stroke, total infarct volume
was similar, yet cortical infarct volume was 4-fold greater
in IDO KO than WT mice, consistent with IDO enhancing
collateral blood flow. In functional studies, the IDO sub-
strate tryptophan dilated pre-constricted arteries only if
active IDO and an intact endothelium were present,
whereas the IDO product kynurenine relaxed pre-con-
stricted rings independent of an intact endothelium.
Mechanistic studies revealed kynurenine to relax arteries
via activation of soluble guanylate cyclase.
Conclusion
This study reveals IDO-mediated tryptophan metabolism
to kynurenine as a previously unrecognized and impor-
tant pathway contributing to the regulation of vascular
tone in the setting of inflammation.
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